Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials | Zendy

Richard Langley | Zendy; Boni E. Elewski | Zendy; Mark Lebwohl | Zendy; Kristian Reich | Zendy; C.E.M. Griffiths | Zendy; Kim Papp | Zendy; L. Puig | Zendy; Hidemi Nakagawa | Zendy; Lynda Spelman | Zendy; Bárður Sigurgeirsson | Zendy; Enrique Rivas | Zendy; TsenFang Tsai | Zendy; Norman Wasel | Zendy; Stephen K. Tyring | Zendy; Thomas Salko | Zendy; Isabelle Hampele | Zendy; Marianne Notter | Zendy; Alexander Karpov | Zendy; Silvia Helou | Zendy; C. Papavassilis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Author(s) -

Richard Langley,

Boni E. Elewski,

Mark Lebwohl,

Kristian Reich,

C.E.M. Griffiths,

Kim Papp,

L. Puig,

Hidemi Nakagawa,

Lynda Spelman,

Bárður Sigurgeirsson,

Enrique Rivas,

TsenFang Tsai,

Norman Wasel,

Stephen K. Tyring,

Thomas Salko,

Isabelle Hampele,

Marianne Notter,

Alexander Karpov,

Silvia Helou,

C. Papavassilis

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1314258

Subject(s) - secukinumab , medicine , psoriasis , psoriasis area and severity index , etanercept , placebo , dosing , dermatology life quality index , clinical endpoint , dermatology , clinical trial , psoriatic arthritis , tumor necrosis factor alpha , pathology , alternative medicine

Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research